Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-sparing Balanced Propofol Analgosedation for Colonoscopy: a Randomized Controlled Trial of a Structured Sedation Protocol

NCT07885059 is registered in ClinicalTrials.gov with University of Split, School of Medicine as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07885059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-sparing Balanced Propofol Analgosedation for Colonoscopy: a Randomized Controlled Trial of a Structured Sedation Protocol
Lead sponsor
University of Split, School of Medicine
Phase
Not applicable
Overall status
Completed
Start date
June 5, 2022
Completion date
February 8, 2024
Enrollment
76 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colonoscopy, sedation and analgesia

Arms

As registered; 2 arms.

  • Standard-dose balanced propofol analgosedation Active comparatorStandard-dose balanced propofol analgosedation

    Intravenous midazolam 0.05 mg/kg (maximum 5 mg), followed by fentanyl 0.001 mg/kg and an initial propofol bolus of 1.0 mg/kg. Additional propofol boluses of 10-30 mg were administered according to clinical need. Sedation and monitoring were guided by an anesthesiologist with an anesthesia technician present.

  • Dose-sparing balanced propofol analgosedation ExperimentalDose-sparing balanced propofol analgosedation

    Intravenous midazolam 0.05 mg/kg (maximum 5 mg), followed by fentanyl 0.001 mg/kg and an initial propofol bolus of 0.5 mg/kg. Additional propofol boluses of 10-30 mg were administered according to clinical need. Sedation and monitoring were guided by a gastroenterologist trained in advanced life support and airway management, with an anesthesia technician present and an anesthesiologist immediately available if required.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Patient satisfaction At completion of post-procedural recovery on the day of colonoscopy.

    Patient satisfaction was assessed using a study-specific four-item questionnaire. Two items assessed satisfaction with the colonoscopy procedure and satisfaction with analgosedation using separate 11-point numerical rating scales ranging from 0 (completely dissatisfied) to 10 (extremely satisfied). Two additional binary items assessed whether the participant would recommend the same approach to relatives or friends and whether the participant would agree to undergo colonoscopy using the same approach again.

  • Incidence of clinically relevant respiratory adverse events From administration of sedation through completion of monitored post-procedural recovery on the day of colonoscopy.

    Incidence of protocol-defined respiratory adverse events, reported by event type. Respiratory events included apnea lasting more than 30 seconds, oxygen saturation below 90%, respiratory rate below 10 or above 20 breaths per minute, end-tidal CO2 below 35 mmHg, and the need for airway-opening interventions. Apnea lasting more than 30 seconds was analyzed as the principal respiratory safety endpoint.

Lead sponsor's other trials

University of Split, School of Medicine, most recent start first.

Similar trials

Same condition (Agnosia) and phase, most recent start first.